Pernix Therapeutics (PTX) Misses Q1 EPS by 36c, Withdraws Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
May 5, 2016 8:01 AM EDTPernix Prescriptions DirectTM Achieves Increased Penetration
MORRISTOWN, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (Pernix or the Company), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2016.
First Quarter 2016 Financial Highlights:
Net Revenue decreased 4% year-over-year to $32.5 million, principally due to lower sales volumes and higher managed care rebates for Treximet® and Silenor®Gross Margin of 65% was comparable to the first quarter 2015Adjusted EBITDA... More